The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers

The use of immune checkpoint blockade (ICB) using antibodies against programmed death receptor (PD)-1, PD ligand (PD-L)-1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has redefined the therapeutic landscape in solid tumors, including skin, lung, bladder, liver, renal, and breast tumors. However, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lingling, Liu, Jiewei, Chen, Jiang, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686226/
https://www.ncbi.nlm.nih.gov/pubmed/34930377
http://dx.doi.org/10.1186/s13045-021-01218-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686226/
https://www.ncbi.nlm.nih.gov/pubmed/34930377
http://dx.doi.org/10.1186/s13045-021-01218-8

Ejemplares similares